Publication List 16-01-06

Publications
Cumulative Impact Factor: 168.1
Original Articles
OA-1 Wenzel RR, Spieker LE, Su Q, Lüscher TF, Noll G (1998). Inhibition of muscle sympathetic nerve activity
by moxonidine in patients with essential hypertension. Hypertension 32:1022-7. Impact Factor: 5.6
OA-2 Spieker LE, Noll G, Lüscher TF (2000). Efficacy and tolerability of fluvastatin and bezafibrate in patients
with hyperlipidemia and persistantly high triglyceride levels. J Cardiovasc Pharmacol 35:361-5. Impact
Factor: 1.9
OA-3 Spieker LE, Noll G, Mitrovic V, Pacher R, Schulze M, Muntwyler J, Schalcher C, Kiowski W, Lüscher TF
(2000). Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients
with congestive heart failure. J Am Coll Cardiol 35:1745-52. Impact Factor: 7.6
OA-4 Spieker LE, Corti R, Binggeli C, Lüscher TF, Noll G (2000). Baroreceptor dysfunction induced by nitric
oxide synthase inhibition in man. J Am Coll Cardiol 36:213-8. Impact Factor: 7.6
OA-5 Binggeli C, Duru F, Corti R, Sudano I, Spieker LE, Turina A, Westermann P, Ostermeier M, Rahn M,
Luscher TF, Noll G, Candinas R (2000). Autonomic nervous system-controlled cardiac pacing: a
comparison between intracardiac impedance signal and muscle sympathetic nerve activity. Pacing Clin
Electrophysiol 23:1632-7. Impact Factor: 1.4
OA-6 Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Ruschitzka F, Corti R, Lüscher TF,
Noll G (2002). High-density lipoprotein restores endothelial function in hypercholesterolemic men.
Circulation 105:1399-402. Impact Factor: 11.2
OA-7 Spieker LE, Hürlimann D, Ruschitzka F, Corti R, Enseleit F, Shaw S, Hayoz D, Deanfield JE, Lüscher TF,
Noll G (2002). Mental stress induces prolonged endothelial dysfunction via endothelin A receptors.
Circulation 105:2817-20. Impact Factor: 11.2
OA-8 Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Béchir M, Spieker LE, Neidhart M,
Michel BA, Gay RE, Lüscher TF, Gay S, Ruschitzka F (2002). Anti-tumor necrosis factor-α treatment
improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184-7. Impact
Factor: 11.2
OA-9 Corti R, Binggeli C, Sudano I, Spieker LE, Hänseler E, Ruschitzka F, Chaplin WF, Lüscher TF, Noll G
(2002). Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeine
content. Role of habitual versus nonhabitual drinking. Circulation 106:2935-40. Impact Factor: 11.2
OA-10 Chenevard R, Hürlimann D, Béchir M, Enseleit F, Spieker LE, Hermann M, Riesen W, Gay S, Gay R,
Neidhart M, Lüscher TF, Noll G, Ruschitzka F (2003). COX-2 inhibition improves endothelial function in
patients with coronary artery disease. Circulation 107:405-9. Impact Factor: 11.2
OA-11 Binggeli C, Spieker LE, Corti R, Sudano I, Stojanovic V, Hayoz D, Lüscher TF, Noll G (2003). Statins
enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: A monitoring
test of endothelial dysfunction for clinical practice? J Am Coll Cardiol 41:71-7. Impact Factor: 7.6
OA-12 Béchir M, Binggeli C, Corti R, Chenevard R, Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2003).
Dysfunctional baroreflex regulation of sympathetic nerve activity in patients with vasovagal syncope.
Circulation 107:1620-5. Impact Factor: 11.2
OA-13 Spieker LE, Lüscher TF, Noll G (2003). ET(A) receptors mediate vasoconstriction of large conduit arteries
during reduced flow in man. J Cardiovasc Pharmacol 42;315-8. Impact Factor: 1.9
OA-14 Spieker LE, Ruschitzka F, Badimon JJ, Noll G, Corti R (2004). Shear stress-dependent platelet function
after LDL cholesterol apheresis. Thrombosis Research 113:395-8. Impact Factor: 1.7
OA-15 Hermann F, Forster A, Chenevard R, Enseleit F, Hurlimann D, Corti R, Spieker LE, Frey D, Hermann M,
Riesen W, Neidhart M, Michel BA, Hellermann JP, Gay RE, Luscher TF, Gay S, Noll G, Ruschitzka F.
(2005). Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll
Cardiol 45:461-4. Impact Factor: 7.6
OA-16 Stojanovic V, Küng F, Spieker LE, Binggeli C, Sudano I, Hayoz D, Lüscher TF, Noll G (2005). Estrogens
increase postischemic hyperemia in the skin microcirculation of healthy women. J Cardiovasc Pharmacol
45:414-7. Impact Factor: 1.9
OA-17 Hermann F, Spieker LE, Ruschitzka F, Sudano I, Hermann M, Binggeli C, Luscher TF, Riesen W, Noll G,
Corti R (2006). Swiss dark chocolate improves endothelial and platelet function in smokers. Heart
92:119-20. Impact Factor: 3.2
OA-18 Sudano I, Spieker LE, Binggeli C, Ruschitzka F, Lüscher TF, Noll G, Corti R (2005). Coffee blunts mental
Publication List of Lukas Spieker – August 29, 2006 – Page 2
stress–induced blood pressure increase in habitual but not in nonhabitual coffee drinkers. Hypertension
46:621-6. Impact Factor: 5.6
OA-19 Flammer A, Spieker LE, Amacker N, Badimon JJ, Sasse B, Ruschitzka F, Noll G, Corti R (2006, In print).
C-reactive protein influences shear stress-dependent platelet adhesion in patients with familiar
hypercholesterolemia and coronary artery disease undergoing LDL apheresis. Thrombosis and
Haemostasis. Impact Factor: 4.5
OA-20 Maas R, Quitzau K, Schwedhelm E, Spieker LE, Rafflenbeul W, Steenpass A, Luscher TF, Boger RH
(2006). Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with
coronary artery disease and mild hypercholesterolemia. Atherosclerosis [Epub ahead of print] Impact
Factor: 3.8
Cumulative Impact Factor (Original Articles): 128.8
Review Articles and Editorials
RA-1 Spieker LE, Binggeli C, Lüscher TF, Noll G (1997). Mitleid und Herzschmerz: Neues vom Sympathikus.
Schweiz Med Wschrft 127:1986-1992. Impact Factor: 1.2
RA-2 Spieker LE, Lüscher TF, Noll G (2000). Das sympathische Nervensystem bei der arteriellen Hypertonie:
Verbindung von Seele und Kreislauf? Medizinspiegel 3:7-12. Impact Factor: –
RA-3 Spieker LE, Noll G, Ruschitzka F, Maier W, Lüscher TF (2000). Working under pressure – The
endothelium in arterial hypertension. J Hum Hypertens 14:617-630. Impact Factor: 1.4
RA-4 Spieker LE, Lüscher TF, Noll G (2000). Homocystein als kardiovaskulärer Risikofaktor. Kardiovaskuläre
Medizin 3:184-95. Impact Factor: –
RA-5 Corti R, Binggeli C, Sudano I, Spieker LE, Wenzel RR, Lüscher TF, Noll G (2000). The beauty and the
beast: Aspects of the autonomic nervous system. News In Physiological Sciences 15:125-129. Impact
Factor: 3.7
RA-6 Spieker LE, Noll G, Lüscher TF (2001). Therapeutic potential of endothelin receptor antagonists in
cardiovascular disorders. Am J Cardiovasc Drugs 1;293-303. Impact Factor: –
RA-7 Spieker LE, Noll G, Ruschitzka F, Lüscher TF (2001). Endothelin receptor antagonists in congestive heart
failure – Blocking the beast while leaving the beauty untouched? Heart Fail Rev 6:301-15. Impact
Factor: –
RA-8 Spieker LE, Lüscher TF, Noll G (2001). Beyond traditional risk factors: Homocystein and atherosclerosis.
Heartdrug 1:160-8. Impact Factor: –
RA-9 Spieker LE, Lüscher TF, Noll G (2001). Current strategies and perspectives for correcting endothelial
dysfunction in atherosclerosis. J Cardiovasc Pharmacol. 38(Suppl 2):S35-41. Impact Factor: 1.9
RA-10 Lüscher TF, Spieker LE, Noll G, Cosentino F (2001). Vascular effects of newer cardiovascular drugs:
Focus on nebivolol and ACE-inhibitors. J Cardiovasc Pharmacol. 38(Suppl 3):S3-11. Impact Factor: 1.9
RA-11 Spieker LE, Noll G, Ruschitzka F, Lüscher TF (2001). Endothelin receptor antagonists in congestive heart
failure – A new therapeutic principle for the future? J Am Coll Cardiol 37:1493-505. Impact Factor: 7.6
RA-12 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2001). Die Diagnose der Herzinsuffizienz. Therapiewoche
17:473-9. Impact Factor: –
RA-13 Spieker LE, Lüscher TF (2001). Kardiovaskuläre Prävention – kulinarisch oder klinisch? Kardiovaskuläre
Medizin 4:227-34. Impact Factor: –
RA-14 Spieker LE, Eberli FR, Buser P, Mach F, Beer J, Urban P, Noll G, Rickenbacher P, Pfisterer M, Meier B,
Lüscher TF (2002). Plättchenhemmung durch Thienopyridine beim akuten Koronarsyndrom – praktische
Empfehlungen aufgrund der CURE Studie. Kardiovaskuläre Medizin 5:61-71. Impact Factor: –
RA-15 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2002). The management of hyperuricemia and gout in
patients with congestive heart failure. European J Heart Failure 4:403-10. Impact Factor: 2.9
RA-16 Spieker LE, Lüscher TF (2003). Will endothelin receptor antagonists have a role in heart failure? Med
Clin N Am 87:459-74. Impact Factor: 1.6
RA-17 Spieker LE, Lüscher TF (2003). Endothelin receptor antagonists in heart failure – A refutation of a bold
conjecture? European Journal of Heart Failure 5;415-7. Impact Factor: 2.9
RA-18 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2003). Medikamentöse Therapie der Herzinsuffizienz.
Cardiovasc 3;28-35. Impact Factor: –
RA-19 Spieker LE, Corti R, Hellermann JP, Eberli FR, Noll G, Lüscher TF. (2003) Niedermolekulare Heparine
Publication List of Lukas Spieker – August 29, 2006 – Page 3
RA-20
RA-21
RA-22
RA-23
RA-24
RA-25
RA-26
RA-27
RA-28
RA-29
RA-29
RA-30
RA-31
RA-32
RA-33
RA-34
beim akuten Koronarsyndrom – Ist Enoxaparin überlegen? Kardiovaskuläre Medizin 6:238-47. Impact
Factor: –
Spieker LE, Noll G (2003). Pathophysiologische Herz-Kreislaufveränderungen bei Stress und Depression.
Therapeutische Umschau 60:667-72. Impact Factor: –
Spieker LE, Ruschitzka F, Noll G (2003). HDL-Cholesterin bei Atherosklerose – Zuwenig des Guten.
Schweizerisches Medizin Forum 39:920-6. Impact Factor: –
Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2004). HDL and inflammation in atherosclerosis. Current
Drug Target – Immune, Endocrine and Metabolic Disorders 4:51-57. Impact Factor: –
Corti R, Spieker LE, Mach F, Erne P, Moccetti T, Beer J, Urban P, Buser P, Rickenbacher P, Pfisterer M,
Eberli FR, Bertel O, Meier B, Lüscher TF (2004). Plättchenhemmung durch Thienopyridine beim akuten
Koronarsyndrom und nach perkutaner koronarer Intervention – praktische Empfehlungen.
Kardiovaskuläre Medizin 7;159-73. Impact Factor: –
Spieker LE, Lüscher TF (2004). Die Rolle der Angiotensin II-Antagonisten in der antihypertensiven
Pharmakotherapie. Ars Medici 12;595-8. Impact Factor: –
Spieker LE (2004). Das Herz beim metabolischen Syndrom. Kardiovaskuläre Medizin 7:317-24. Impact
Factor: –
Spieker LE (2004). Vorhersage kardiovaskulärer Ereignisse: Endothelfunktion als Surrogatmarker.
Cardiovasc 4;43. Impact Factor: –
Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia
G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ (2005).
Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A
statement by the Working Group on Endothelins and Endothelial Factors of the European Society of
Hypertension. J Hypertens 23:233-246. Impact Factor: 1.6
Spieker LE, Stacchi R, Corti R, Noll G (2005). Der Cannabinoid-Rezeptor-Antagonist Rimonabant.
Kardiovaskuläre Medizin 8;18-22. Impact Factor: –
Sudano I, Binggeli C, Spieker LE, Lüscher TF, Ruschitzka F, Noll G, Corti R (2005). Cardiovascular effects
of coffee: is it a risk factor? Prog Cardiovasc Nurs 20:65-9.Impact Factor: –
Sudano I, Spieker LE, Corti R, Weber R, Lüscher TF (2006). Cardiovascular disease in HIV infection. Am
Heart J 151:1147-55. Impact Factor: 3.6
Spieker LE, Noll G, Ruschitzka F, Lüscher TF (Submitted). The challenge of diagnosing heart failure.
Hollenberg NK, Schmitz H, Spieker LE, Lüscher TF, MacDonald I, Poulter N (In press). Dietary flavonoids
and cardiovascular risk. British Journal of Cardiology.
Hermann F, Ruschitzka F, Spieker L, Sudano I, Noll G, Corti R (2005). The sweet secret of dark
chocolate. Ther Umsch 62:635-7. Impact Factor: –
Corti R, Sudano I, Spieker L, Binggeli C, Hermann F, Toenz D, Noll G (2005). Coffee – poison or
medicine? Ther Umsch 62:629-33. Impact Factor: –
Sudano I, Spieker LE, Hermann F, Flammer A, Corti R, Noll G, Luscher TF (2006). Protection of
endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol
47 Suppl 2:S136-50. Impact Factor: 1.9
Cumulative Impact Factor (Review Articles): 35.4
Case Reports
CR-1 Spieker LE, Sütsch G (2003). Eine 22-jährige Frau mit akutem Myokardinfarkt. Kardiovaskuläre Medizin
6:162-4. Impact Factor: –
CR-2 Karadag B, Spieker LE, Schwitter J, Ruschitzka F, Noll G, Lüscher TF, Corti R (2004). Lyme carditis:
restitutio ad integrum documented by cardiac MRI. Cardiology in Review 12:185-7. Impact Factor: –
CR-3 Spieker LE, Hufschmid U, Oechslin E, Jenni R (2004). Double aortic and pulmonary valves: an artifact
generated by ultrasound refraction. J Am Soc Echocardiogr 17:786-7. Impact Factor: 1.4
CR-4 Spieker LE, Jenni R (2004). An apparently immobile mitral valve prosthesis leaflet. J Am Soc
Echocardiogr 17;905. Impact Factor: 1.4
CR-5 Spieker LE, Maier W, Jenni R (2004). Eine Frau mit intramyokardialer Verkalkung. Kardiovaskuläre
Medizin 7:218-20. Impact Factor: –
CR-6 Karadag B, Spieker LE, Wildermut S, Maier W, Böhm T, Lüscher TF, Corti R (2005). Sudden death in a
Publication List of Lukas Spieker – August 29, 2006 – Page 4
CR-7
CR-8
CR-9
soccer player: A unique case of anomalous coronary origin detected by 16-slice computed tomography
imaging. Heart and Vessels 20:116-9. Impact Factor: 0.4
Spieker LE, Karadag B, Binggeli C, Corti R (2005). Rapid progression of atherosclerotic coronary artery
disease in patients with HIV infection. Heart and Vessels 20;171-4. Impact Factor: 0.4
Spieker LE, Corti R, Noll G (2005). Eine Frau mit Bradykardie und Schwäche. Schweiz Med Forum
5;60-2. Impact Factor: –
Spieker LE, Burger P, Ritschard T, Noti C, Corti R (In print). Ein gebrochenes Herz nach einem Streit mit
der Schwiegermutter: die Stress-induzierte Kardiomyopathie. Kardiovaskuläre Medizin. Impact Factor: –
Cumulative Impact Factor (Case Reports): 3.6
Book Chapters
B-1
Spieker LE, Noll G, Ruschitzka F, Maier W, Lüscher TF. Endothelial function in hypertension. In: Schwartz
CJ, Born GVR (Eds). Occlusive arterial disease. The interfaces among dyslipidemia, hypertension and
diabetes. Schattauer (2001).
B-2
Spieker LE, Lüscher TF. Hypertension and blood vessels: from diagnosing vascular events to the
assessment of endothelial dysfunction. In: Birkenhäger WH, Robertson JIS, Zanchetti A (Eds). Handbook
of Hypertension, Vol. 22: Hypertension in the twentieth century. Elsevier (2004).
B-3
Spieker LE, Lüscher TF. Target Organ Damage: Endothelium and Vessels. In: Distance-learning course:
Clinical Hypertension (2004). www.emn.net
B-4
Spieker LE, Lüscher TF. Endothelium in hypertension: Nitric oxide. In: Oparil S, Weber MA (Eds).
Hypertension: A companion to Brenner and Rector’s The Kidney, 2nd Ed. Elsevier (2005).
B-5
Spieker LE, Lüscher TF. Endothelium, vascular smooth muscle, perturbations of cell membranes and
signal transduction in hypertension. In: Battegay E, Lip GYH, Bakris GL (Eds.). Hypertension: Principles
and practice. Dekker (In press).
B-6
Lüscher TF, Noll G, Spieker LE, Corti R, Pepine CJ. Coronary spasm and atherothrombosis. In: Fuster V,
Nabel EG, Topol EJ (Eds). Atherothrombosis and coronary artery disease, 2nd Ed. Lippincott Williams &
Wilkins (2005).
B-7
Spieker LE, Lüscher TF. Protection of endothelial function (2005). Handbook of experimental
pharmacology Handb Exp Pharmacol 170:619-44.
Invited Lectures and Presentations (Selection)
P-1
European Society of Cardiology (ESC), Stockholm 1997. Variability of muscle sympathetic nerve activity,
arterial blood pressure, and heart rate.
P-2
Schweizerische Gesellschaft für Kardiologie (SGK), Interlaken 1998. Wirkung von NO-SyntheseHemmung auf Hämodynamik und Sympathikus.
P-3
Lipid-Symposium, Zürich 1999. Hyperhomocysteinämie: klinische Bedeutung und Therapie.
P-4
6th Endothelin-Meeting, Montreal 1999. Acute hemodynamic and neurohumoral effects of selective ETA
receptor blockade in patients with congestive heart failure.
P-5
European Society of Cardiology (ESC), Barcelona 1999. Effects of NO synthase inhibition on muscle
sympathetic nerve activity and hemodynamics in man.
P-6
American Heart Association (AHA), New Orleans 2000. High-density lipoprotein restores endothelial
function in hypercholesterolemic men.
P-7
American College of Cardiology (ACC), Anaheim 2000. Baroreceptor dysfunction induced by nitric oxide
synthase inhibition in man.
P-8
Lipid-Symposium, Zürich 2000. Stress und Endothelfunktion.
P-9
European Society for Clinical Investigation (ESCI), Barcelona 2001. HDL restores endothelial function in
hypercholesterolemic men.
P-10 Schweizerische Gesellschaft für Kardiologie (SGK), Zürich 2001. Endothelin-1 mediates vasoconstriction
of large conduit arteries during reduced flow via endothelin A receptors in man.
P-11 Lipid-Symposium, Zürich 2002. Neue Cholesterinsenker.
P-12 Evidence-based Cardiology, Feusisberg 2002. The patient with multiple risk factors.
P-13 The Menarini Series on Atherosclerosis, Naples 2002. Pharmacological modulation of the endothelium
Publication List of Lukas Spieker – August 29, 2006 – Page 5
P-14
P-15
P-16
P-17
P-18
P-19
P-20
P-21
P-22
P-23
P-24
P-25
P-26
P-27
P-28
P-29
P-30
P-31
P-32
P-33
P-34
P-35
P-36
in cardiovascular disease.
1st International Meeting on ADMA as a Cardiovascular Risk Factor, Hamburg 2002. Pharmacotherapy
of coronary endothelial dysfunction.
Klinisch-wissenschaftliche Konferenz, USZ, Zürich 2002. HDL – Protektive Wirkung über den
Lipidstoffwechsel hinaus.
American Heart Association (AHA), Chicago 2002. Mental stress induces prolonged endothelial
dysfunction via endothelin A receptors.
Zürich 2002. Angiotensin II-Rezeptor Antagonisten in der Prävention kardiovaskulärer EndorganSchäden.
Herzkreislauftag, Zürich 2002. Klinische Entscheidungen bei multimorbiden Herzpatienten.
Zürich 2003. Duale Cholesterintherapie mit Ezetimibe und Statinen.
American College of Cardiology (ACC), Chicago 2003. Marked coronary endothelial dysfunction in
patients with low HDL and elevated C-reactive protein.
Schweizerische Gesellschaft für Kardiologie, Lausanne 2003. AIDS – eine kardiovaskuläre Krankheit?
Hellenic Cardiology Society, Santorini 2003. Inflammation and atheroslerosis – Does the endothelium
provide a link?
Zürich 2003. Arterielle Hypertonie – Optimaler medikamentöser Endorganschutz.
Schweizerische Gesellschaft für Innere Medizin 2003. Pathophysiologie der Herz-Kreislaufveränderungen
bei Depression und Stress.
Aging Forum, Bad Aibling 2003. Mental stress and atherosclerosis.
Tag der offenen Tür, Kardiologie USZ 2003. Wie bleibt mein Herz gesund?
6th Winter Meeting, Working Group on Heart Failure, Swiss Cardiology Society, Mürren 2004. Heart
failure therapy in post-MI and DCM patients: Two pairs of shoes?
Zürich 2004. Cholesterintherapie – wie weiter?
Controversies in Cardiology, Bern 2004. Erectile Dysfunction – an unsolved problem.
Schweizerische Gesellschaft für Kardiologie, Basel 2004. Metabolic syndrome – the cardiologists view.
Evidence-based Cardiology, Feusisberg 2004. The patient with multiple risk factors.
Evidence-based Cardiology, Feusisberg 2004. Treatment of acute coronary syndrome.
Symposium für Akutgeriatrie, Stadtspital Waid, Zürich 2005. Phosphodiesterasehemmer – kein Problem
im Alter.
Herzkreislauf-Erkrankungen. Kurs für Pflegende. Universitätsstpital Zürich, 2004 und 2005.
Fallvorstellung, Herzinsuffizienz-Update, Grenchen 2005.
Herznotfall: aus der Sicht des Praktikers. HerzZentrum Bern, Bern 2006.